相似文献
1
Temozolomide and MGMT forever?
Neuro Oncol. 2010 Mar;12(3):219-20. doi: 10.1093/neuonc/noq016.
2
Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Oncol Rep. 2015 Nov;34(5):2715-21. doi: 10.3892/or.2015.4232. Epub 2015 Aug 27.
3
Long-range gene regulation network of the MGMT enhancer modulates glioma cell sensitivity to temozolomide.
J Genet Genomics. 2021 Oct 20;48(10):946-949. doi: 10.1016/j.jgg.2021.06.015. Epub 2021 Jul 14.
4
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Neuro Oncol. 2015 Nov;17(11):1425-7. doi: 10.1093/neuonc/nov198. Epub 2015 Sep 15.
5
MGMT promoter methylation in pediatric high-grade gliomas.
Childs Nerv Syst. 2011 Jan;27(1):7-8. doi: 10.1007/s00381-010-1313-9. Epub 2010 Oct 30.
6
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
J Neurooncol. 2008 Sep;89(2):179-85. doi: 10.1007/s11060-008-9600-y. Epub 2008 Apr 23.
7
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Clin Cancer Res. 2015 May 1;21(9):2057-64. doi: 10.1158/1078-0432.CCR-14-2737. Epub 2015 Feb 5.
8
Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
Cancer Med. 2016 Mar;5(3):486-99. doi: 10.1002/cam4.614. Epub 2016 Jan 18.
9
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Neurol Med Chir (Tokyo). 2007 Aug;47(8):341-9; discussion 350. doi: 10.2176/nmc.47.341.
10
Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Oncotarget. 2015 Oct 6;6(30):29456-68. doi: 10.18632/oncotarget.4909.
引用本文的文献
1
Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
Pituitary. 2012 Sep;15(3):276-87. doi: 10.1007/s11102-011-0363-7.
本文引用的文献
1
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
Neuro Oncol. 2010 Mar;12(3):289-96. doi: 10.1093/neuonc/nop030. Epub 2010 Jan 11.
2
O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications.
Neuro Oncol. 2010 Mar;12(3):283-8. doi: 10.1093/neuonc/nop050. Epub 2010 Feb 1.
3
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Nat Rev Neurol. 2010 Jan;6(1):39-51. doi: 10.1038/nrneurol.2009.197. Epub 2009 Dec 8.
4
Rechallenge with temozolomide in patients with recurrent gliomas.
J Neurol. 2009 May;256(5):734-41. doi: 10.1007/s00415-009-5006-9. Epub 2009 Feb 25.
5
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Cancer. 2008 Oct 15;113(8):2152-7. doi: 10.1002/cncr.23813.
6
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
J Clin Oncol. 2007 Aug 1;25(22):3357-61. doi: 10.1200/JCO.2007.10.7722.
7
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Br J Cancer. 2006 Nov 6;95(9):1155-60. doi: 10.1038/sj.bjc.6603376. Epub 2006 Oct 3.
8
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330.
9
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.
Br J Cancer. 2000 Sep;83(5):588-93. doi: 10.1054/bjoc.2000.1316.
10
Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.
J Clin Oncol. 1999 Sep;17(9):2762-71. doi: 10.1200/JCO.1999.17.9.2762.
Zotero 插件